华南预防医学 ›› 2019, Vol. 45 ›› Issue (4): 327-331.doi: 10.13217/j.scjpm.2019.0327

• 论著 • 上一篇    下一篇

四川省广元地区慢性粒细胞白血病患者治疗情况及生活质量分析

黄秀莲, 徐鸿, 杨佳红, 于婷   

  1. 四川省广元市中心医院,四川 广元 628000
  • 收稿日期:2019-03-09 出版日期:2019-08-20 发布日期:2019-08-28
  • 作者简介:黄秀莲(1974—)女,大学本科,主管护师,主要研究方向:血液病护理

Treatment and quality of life in patients with chronic myelogenous leukemia in Guangyuan, Sichuan Province

HUANG Xiu-lian, XU Hong, YANG Jia-hong, YU Ting   

  1. Guangyuan Central Hospital of Sichuan Province,Guangyuan 628000,China
  • Received:2019-03-09 Online:2019-08-20 Published:2019-08-28

摘要: 目的 探讨四川省广元地区慢性粒细胞白血病(CML)患者的治疗情况及生活质量,为该类患者的临床治疗及健康管理提供依据。方法 采用便利抽样的方法对2015—2018 年在广元市中心医院、广元市中医院和广元市肿瘤医院复诊的CML患者进行调查。采用临床资料调查表和白血病生活质量评估量表对患者进行问卷调查,采用单、多因素分析方法对患者生活质量的影响因素进行分析。结果 本研究共纳入CML患者185例,平均年龄(41.62 ± 15.47)岁,男性和女性分别为98(占52.97%)、87例(占47.03%)。185例患者中治疗药物为伊马替尼的94例(占50.81%)、干扰素-α联合阿糖胞苷57例(占30.81%)、羟基脲单药34例(占18.38%)。CML患者总体生活质量评分为(122.47 ± 14.43)分,得分率为(65.37 ± 6.25)%,在各维度评分中社会/家庭维度得分率最高,为(76.35 ± 5.17)%,功能模块维度得分率最低,为(55.87 ± 5.48)%。多元线性回归分析结果显示,年龄越小、无伴随疾病、有医疗保险、家庭人均月收入越高、血红蛋白数值高、红细胞计数高、治疗药物为伊马替尼的CML患者其生活质量较高(标准偏回归系数分别为0.358、0.765、0.546、0.456、0.469、0.462、0.486)。结论 四川广元地区CML患者生活质量不高,临床治疗以伊马替尼治疗、干扰素-α联合阿糖胞苷和羟基脲为主,可通过多种方式提高患者的生命质量。

关键词: 慢性粒细胞白血病, 治疗效果, 生活质量, 影响因素

Abstract: Objective To investigate the treatment and factors influencing quality of life (QOL) in patients with chronic myelogenous leukemia (CML) in Guangyuan, Sichuan Province. Methods CML patients who were re-examined in Guangyuan Central Hospital, Guangyuan Hospital of Traditional Chinese Medicine and Guangyuan Tumor Hospital from 2015 to 2018 were enrolled in this study by using convenient sampling method. Questionnaire survey was conducted using clinical data questionnaire and leukemia QOL assessment. Univariate and multivariate logistic regressions were used to analyze factors influencing QOL. Results A total of 185 patients with CML were included in the survey, with an average age of (41.62 ± 15.47) years, including 98 (52.97%) males and 87 (47.03%) females. Among the 185 patients, 94 (50.81%) patients were treated with imatinib, 57 (30.81%) with alpha-interferon combined with cytarabine, and 34 (18.38%) with hydroxycarbamide monotherapy. The overall QOL score of CML patients was (122.47 ± 14.43), with a score rate of (65.37 ± 6.25)%. The social/family dimension scored the highest (76.35 ± 5.17)% and the function module scored the lowest (55.87 ± 5.48)%. In the multivariate linear regression model, that patients with younger age, without concomitant diseases, with medical insurance, higher average monthly family income, higher hemoglobin, higher red blood cell count, and treated with imatinib had higher QOL (standard partial regression coefficients: 0.358, 0.765, 0.546, 0.456, 0.469, 0.462, and 0.486, respectively). Conclusion The QOL in patients with CML in Guangyuan City, Sichuan Province was not high. It is suggested to use imatinib therapy, interferon-alpha combined with cytidine and hydroxyurea as the main clinical treatments to improve the QOL in patients with CML.

Key words: Chronic myelogenous leukemia, Treatment, Quality of life, Influencing factors

中图分类号: 

  • R181.3+7